Heron Therapeutics Inc vs Transocean Ltd — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Transocean Ltd trades at $5.06 (market cap $5.56B). The key difference: Transocean Ltd is far larger — about 60.8× Heron Therapeutics Inc's market cap, and Transocean Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | RIG | |
|---|---|---|
Market Cap | $91.46M | $5.56B |
Sector | Health | Technology |
52-Week High | $1.96 | $7.58 |
52-Week Low | $0.39 | $2.64 |
Enterprise Value | $189.36M | $10.50B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Transocean Ltd. (RIG) trades at $5.02, down 2.33% on the day, reflecting a bearish technical trend. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion in revenue, with a negative net income margin of -66.79%. Recent news highlights a significant $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and generating synergies. Analyst consensus is mixed, with a $7.00 price target suggesting potential upside from current levels.
The outlook for RIG hinges on successful execution of its merger and contract backlog conversion to profitability. Opportunities include a strong $7 billion backlog and operational momentum, but risks persist from sustained net losses, high debt, and oil price volatility. Investors should weigh the potential for deleveraging and synergy benefits against ongoing profitability challenges.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →